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ABSTRACT: Artifical metalloenzymes combine the reac-
tivity of small molecule catalysts with the selectivity of 
enzymes, and new methods are required to tune the cata-
lytic properties of these systems for an application of 
interest. Structure-based computational design could help 
to identify amino acid mutations leading to improved 
catalytic activity and enantioselectivity. Here we describe 
the application of Rosetta Design for the genetic optimi-
zation of an artificial transfer hydrogenase (ATHase 
hereafter), [(5-Cp*)Ir(pico)Cl]  WT hCA II (Cp* = 
Me5C5–), for the asymmetric reduction of a cyclic imine, 
the precursor of salsolsidine. Based on a crystal structure 
of the ATHase, computational design afforded four 
hCAII variants with protein backbone-stabilizing and 
hydrophobic cofactor-embedding mutations. In dansyla-
mide-competition assays, these designs showed 46-64-
fold improved affinity for the iridium pianostool complex 
[(5-Cp*)Ir(pico)Cl]. Gratifyingly, the new designs 
yielded a significant improvement both in activity and 
enantioselectivity (from 70 % ee (WT hCA II) to up to 92 
% ee and a fourfold increase in total turnover number) 
for the production of (S)-salsolidine. Introducing addi-
tional hydrophobicity in the Cp*-moiety of the Ir-catalyst 
provided by adding a propyl substituent on the Cp* moi-
ety yields the most (S)-selective (96 % ee) ATHase re-
ported to date. X-ray structural data indicate that the high 
enantioselectivity results from embedding the piano stool 
moiety within the protein, consistent with the computa-
tional model.  
 
 
Introduction 
Over the past decade, artificial metalloenzymes have 
gained attention as attractive alternatives to both homo-
geneous catalysts and enzymes.1–11 These hybrid cata-
lysts result from anchoring an organometallic cofactor 
within a protein environment, thus augmenting the en-
zymatic repertoire with reactions or reaction pathways 
accessible only to organometallic catalysts.12–28 Optimi-
zation of the catalytic performance can be achieved by 
combining both chemical means (i.e. variation of the 
ligand bound to the metal and of the spacer between the 
anchor and the ligand) with genetic means (amino acid 
mutation), Figure 1a. 
      Methods to optimize first generation artificial metal-
loenzymes (hereafter ArMs) are necessary to achieve 
desired catalytic properties. Traditional directed evolu-
tion efforts are powerful but limited because of the small 
number of variants that can be screened in a typical ex-
periment.11,15,29–32 This shortcoming is partially imposed 
by the requirement of purified protein samples to ensure 
the activity of ArMs. Most mutagenesis strategies to date 
have thus relied on structure gazing and educated guess-
ing to identify potential single- and double mutants that 
may improve the catalytic performance.  
   Computational design offers an alternative to high 
throughput directed evolution screening efforts.33–35 The 
library-size limitation of artificial metalloenzymes can be 
circumvented by using computational design principles 
to reduce the vast sequence landscape of the catalyst-
protein interface to a small number of variants that can 
be characterized experimentally. Computational methods 
that rapidly optimize the entire sequence space of the 
cofactor-binding site may offer a more comprehensive 
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Figure 1: Sulfonamide iridium pianostool cofactors (a) and hCAII variants used in this study, including affinities of selected 1 
 hCAII mutants (b). Model of Rosetta Design d4-based on crystal structure of complex [(5-Cp*)Ir(pico)Cl] 1  WT hCA II 
(PDB 3ZP9) (c). Designed backbone-stabilizing H-bonds are represented as green dashed lines.  
approach to designing ArMs with improved performance. 
The Rosetta protein design software is a versatile tool for 
the structure-based computational design of protein-
protein,36 protein-small molecule37 and protein-metal30,38 
interactions, including the creation of artificial 
enzymes.39–42 Recently, Baker and coworkers reported 
the de novo design of a picomolar affinity binding pro-
tein for the steroid digoxigenin.37 Explicit design of H-
bonding and hydrophobic interactions resulted in a high-
ly shape-complementary, low micromolar affinity bind-
ing protein. Three rounds of directed evolution increased 
binding affinity by more than three orders of magnitude, 
and deep mutational scanning showed that many of the 
first shell binding site residues of the design were opti-
mal for binding. Intrigued by that level of success, we 
hypothesized that Rosetta may also be used to improve a 
cofactor binding site of first generation ArMs. We rea-
soned that a more tightly bound organometallic cofactor 
may lead to a better defined first and second coordination 
sphere that may improve catalytic performance. 
   We recently reported the assembly of Noyori-type pi-
anostool complex [(5-Cp*)Ir(pico)Cl] 1 (Figure 1a,c) 
within wild type human carbonic anhydrase II (hCAII 
hereafter).43 The ArM catalyzes the asymmetric transfer 
hydrogenation of the salsolidine precursor (a cyclic 
imine) into the chiral alkaloid salsolidine with moderate 
enantioselectivity (70 % ee (S)-salsolidine) and a total 
turnover number of 9 at 4 °C (Table 1, entry 4). Although 
the Ir-cofactor binds to hCAII with low nanomolar affini-
ty, the crystal structure of the hybrid catalyst revealed 
that the {Cp*Ir}-moiety is only 30% occupied presuma-
bly due to partial dissociation and/or shallow potential 
energy surface within the active site. We speculate that 
the WT hCA II has limited influence over the active site 
geometry, leading to a poorly defined “active site” 
around the {Ir–H}-catalytic moiety and resulting in a 
modest activity and selectivity.  
   Herein we report our efforts to improve the catalytic 
performance of [(5-Cp*)Ir(pico)Cl] 1  hCA II by using 
the computational design software Rosetta to tailor the 
second coordination sphere around the iridium cofactor. 
Results and Discussion 
The enzyme design module45 of Rosetta was used to 
identify potential mutations that stabilize the [(5-
Cp*)Ir(pico)Cl] 1  hCA II hybrid. The crystal structure 
of complex 1  WT hCAII (PDB ID 3ZP9) was relaxed46 
and the sequence of the protein was optimized for pro-
tein–cofactor interaction energy using fixed-backbone 
sequence design.45 An example RosettaScripts47 XML 
design protocol is provided in the Supplementary Infor-
mation. During design calculations, the native residue 
energies were up-weighted by 1.5 relative to their stand-
ard weight in the score12 or enzdes weight set to prevent 
protein destabilization. Zinc-coordinating His residues 
were fixed in their native conformations. Designable 
residues were restricted to those within 10 Å of the Ir-
catalyst, and residues were not allowed  
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Table 1: Influence of hCAII variants on transfer hydrogenation of isoquinoline substrates with ATHase.a  
aReactions were carried out in the presence of 9.1 mM substrate, 0.104 mM hCAII-mutant, 0.091 mM metal catalyst (1 
mol%), 2.73 M sodium formate, 0.36 M MOPS buffer (pH 7.5) and 1.04 mM ZnSO4 unless otherwise indicated. bNo ZnSO4 
was added. c4 mM substrate were used. ddata from ref.48 See Figure 1 for definition of mutations. 
to mutate to cysteine, aspartate, or glutamate. The ligand 
was extracted from PDB ID 3ZP9 and was converted to a 
Rosetta readable parameters file format using the mol-
file_to_params application of Rosetta. Lennard-Jones 
and solvation parameters for the Ir atom were taken from 
the Unified Force Field.49 Designs were scored using 
score12 and the enzdes weights set with or without elec-
trostatics. Ten separate trajectories of Monte Carlo design 
were run, and four designs were selected for experi-
mental characterization based on total energy, manual 
inspection, occurrence of mutated residue identities in a 
multiple sequence alignment of hCA II, and the comput-
ed probability of maintaining mutated residue side chain 
conformations in the absence of the cofactor (d1, d2, d3, 
d4, Figure 1 b,c).50  
   The four selected designs include between six and eight 
amino acid mutations, predominantly of hydrophobic 
nature that either provide additional shape complementa-
rity and packing interactions between the protein and the 
cofactor (N67W, E69Y, Q92F, L140M, L197M) or stabi-
lize the protein backbone (C205S, A65T, L60V) (Figure 
1b,c). These mutations are clustered within two regions 
on the central -sheet of the protein (Figure 1c). Key 
mutations that directly contact the ligand are L140M on 
-strand 5 and L197M in loop 7,8, which pack against 
the coplanar biaryl moiety of the ligand. Residue C205S 
at the end of loop 7,8 is designed to form an H-bond with 
the carbonyl oxygen of V134 in loop 4,5. Rigidifying the 
Entry hCAII-mutant Metal cata-
lyst 
Substrate Temperature 
[°C] 
Reaction 
Time [h] 
TON ee [%] 
1b 
2b 
3 
4 b, c, d 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
no protein 
no protein 
WT 
WT 
a1 
a2 
a3 
a4 
a4 
d1 
d1 
d2 
d2 
d3 
d3 
d4 
a2 
d3 
d4 
a2 
d1 
a2 
d1 
a2 
d1 
1 
2 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
2 
2 
2 
1 
1 
1 
1 
1 
1 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
4 
4 
5 
5 
6 
6 
RT 
RT 
RT  
4 
4 
4 
4 
RT 
4 
RT 
4 
RT 
4 
RT 
4 
4 
RT 
4 
4 
4 
RT 
4 
RT 
4 
4 
18 
24 
18 
44 
96 
96 
96 
18 
96 
18 
96 
18 
96 
18 
96 
96 
24 
288 
288 
192 
20 
192 
22 
96 
96 
15 
10 
25 
9 
37 
43 
24 
100 
98 
91 
85 
72 
71 
81 
77 
78 
31 
38 
59 
82 
84 
99 
91 
80 
98 
rac 
rac 
58 (S) 
70 (S) 
85 (S) 
86 (S) 
74 (S) 
90 (S) 
94 (S) 
87 (S) 
91 (S) 
84 (S) 
87 (S) 
88 (S) 
91 (S) 
92 (S) 
69 (S) 
94 (S) 
96 (S) 
85 (S) 
60 (S) 
90 (S) 
64 (S) 
75 (S) 
74 (R) 
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 4 
relative orientation of these loops through this hydrogen 
bond likely helps to hold the cofactor in a more defined 
orientation. Residues N67W, E69Y and Q92F are located 
on -strands 2 and 3 which interact with the biaryl group 
and the chelating phenylsulfonamide. Mutation A65T on 
-strand 2 is designed to form an H-bond with the car-
bonyl oxygen of F95. 
   Mutations were introduced into hCAII by stepwise 
mutagenesis of individual amino acids. Besides the four 
Rosetta hCAII designs, we also present four additional 
mutants that include only some of the Rosetta-predicted 
mutations (a1, a2, a3, a4, Figure 1b) but were particular-
ly successful in terms of catalytic performance and might 
help to assess the impact of individual sites.  
   The affinities of five of the hCAII variants for the or-
ganometallic catalyst [(5-Cp*)Ir(pico)Cl] 1 were deter-
mined by colorimetric competition assay with dansyla-
mide (Figure 1b, Supporting Table S7, Supporting Fig-
ures S4 and S5).51,52 All designs showed increased affini-
ties for the cofactor relative to wild-type hCAII. The best 
Rosetta design, d3, binds [(5-Cp*)Ir(pico)Cl] 1 ~64 
times more tightly than WT hCA II does (0.33 nM vs. 21 
nM). This design contains backbone stabilizing residues 
L60V, A65T, L197M and C205S and aromatic mutations 
N67W, E69Y and Q92F, which provide shape comple-
mentarity with the ligand from one side. Back-mutation 
of methionine L197M on -strand 5, as in design d1, 
reduces the affinity by 1.4-fold. Similarly back-mutation 
of E69Y as in d2 reduces the affinity 1.3-fold, highlight-
ing the success of the Rosetta design. Reversion of resi-
due C205S into native cysteine in d2 yields the design 
precursor a4, which has virtually identical cofactor affin-
ity. Interestingly, even a reduced set of only three muta-
tions engineered near one face of the cofactor binding 
site can improve the affinity 22-fold over the wild type 
protein, as highlighted with a2. Together, these results 
suggest that Rosetta Design can be used to improve the 
affinities of organometallic cofactor-protein interactions 
by introduction of bulky hydrophobic residues in the 
cofactor binding site combined with backbone-stabilizing 
mutations. 
   Next, we investigated how the mutants perform in the 
asymmetric transfer hydrogenation of a model substrate, 
the salsolidine precursor 3 (Table 1). Gratifyingly, the 
hCAII mutants with higher affinity for [(5-
Cp*)Ir(pico)Cl] 1 than wild type are both more active 
and more enantioselective. Rosetta designs d1, d2 and 
d3, which have 46-64 fold improved affinity, produce 
(S)-salsolidine with 91, 87 and 91 % ee at 4 °C, respec-
tively (wild type: 70 % ee; Table 1 compare entries 4, 12, 
14 and 16). Performing catalysis at 298 K leads to signif-
icantly higher turnover numbers (TON hereafter): from 
25 for WT-hCAII to 91, 72 and 81 for designs d1, d2 and 
d3, respectively (Table 1 entries, 3, 11, 13, 15). Under 
the same conditions, the free [(5-Cp*)Ir(pico)Cl] 1 
shows only 15 TON. The design precursor a4, which 
differs from d2 by only one mutation (C205S) and has 
virtually identical cofactor affinity, is the best catalyst, 
producing (S)-salsolidine with 94 % ee and a TON of 98 
at 4 °C. This illustrates how distant residues can have 
significant impact on enzyme performance. Saturation 
kinetic parameters were determined for the two most 
active mutants a4 and d1 (kcat = 0.29 ± 0.02 min-1, KM = 
23 ± 3.4 mM and kcat = 0.16 ± 0.01 s-1, KM = 20 ± 2.5 
mM, respectively, Supporting Figure S2). Comparing 
designs a4 and d1, we hypothesize that the presence of a 
glutamate (vs. tyrosine) at position 69 for a4 (vs. d1) 
offers favourable interactions with the iminium form of 
the substrate, contributing to the twofold rate enhance-
ment. In contrast to wild type hCAII43 and a number of 
related streptavidin ATHases,44 no substrate inhibition is 
encountered for a4 and d1, even at 100 mM substrate 
concentration.  
   Taking advantage of the versatile chemogenetic opti-
mization potential of artificial metalloenzymes, we rea-
soned that increased hydrophobic interactions between 
the cofactor and the protein may also be provided by 
introducing a bulkier propyl substituent on the 5-arene 
cap. The metal center of metallocofactor [(5-
Cppropyl)Ir(pico)Cl] 2 (Figure 1a) is more electron-rich 
and bulkier than [(5-Cp*)Ir(pico)Cl] 1, hampering met-
al-hydride formation. This trend is reflected in the slight-
ly reduced activity of [(5-Cppropyl)Ir(pico)Cl] 2 vs. [(5-
Cp*)Ir(pico)Cl] 1 (Table 1, entries 1 and 2). The hCAII 
mutants follow the same general activity and enantiose-
lectivity trends for cofactors [(5-Cppropyl)Ir(pico)Cl] 2 
and [(5-Cp*)Ir(pico)Cl] 1 (Table 1 and Supporting Ta-
ble S3). The most (S)-selective ATHase (96 % ee) was 
obtained combining Rosetta design d4 with [(5-
Cppropyl)Ir(pico)Cl] 2. It is interesting to note that the 
streptavidin-based ATHases typically afford the (R)-
salsolidine. The best (S)-selective streptavidin-based 
ATHase (78 % ee) is [(5-Cp*)Ir(Biot-p-L)Cl]  
S112K.17 
   Despite repeated attempts to crystalize all variants, 
only the hCAII a2 mutant yielded X-ray quality crystals. 
This construct comprises amino acid mutations L140M, 
L197M and C205S. Diffraction data were collected at the 
synchrotron to 1.4 - 1.6 Å resolution for three crystals: i) 
apo-a2, ii) [(5-Cp*)Ir(pico)Cl] 1  a2 and iii) [(5-
Cppropyl)Ir(pico)Cl] 2  a2 (Supporting Table S4 and S5). 
The latter two were obtained by soaking apo-protein 
crystals with the corresponding Ir-catalyst. For all three 
crystal structures, the overall protein structure is virtually 
identical to WT hCAII (0.28 – 0.30 Å RMSD for C and 
C). For apo-a2, high side chain flexibility is found for 
residues L140M and L197M: these adopt two alternative 
conformations  (Supporting Figure S3a and b). The side 
chain of C205S is rotated ~90° around the C-Cbond 
relative to the wild type cysteine and forms an H-bond 
with the carbonyl oxygen of V134 which links loop 7,8 
with loop 4,5. For both structures containing the Ir-
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 5 
cofactor-bound complexes, residual electron density in 
the 2Fo-Fc map is observed in the cone-shaped catalytic 
cavity, indicating the presence of the cofactor. In struc-
ture [(5-Cp*)Ir(pico)Cl] 1  a2, the cofactor was mod-
eled as previously described for the equivalent [(5-
Cp*)Ir(pico)Cl] 1  WT hCAII (Supporting Figure S3a). 
Figure 2: X-ray crystal structure of [(5-
Cppropyl)Ir(pico)Cl] 2  hCAII a2 (PDB 5BRU). The Ir-
cofactor is depicted as stick in orange (iridium, cyan 
sphere; chloride, green sphere) and is contoured with 
2Fo-Fc electron density in blue at 1  and anomalous 
difference density in red at 3 . Mutated amino acid side 
chains are represented as blue sticks.  Upon catalyst 
binding, the side chain conformation of residue F130 
switches from a relaxed state (magenta stick model; 
modeled in the crystal structure of apo-hCAII a2, PDB 
5BRW) to a tense state (grey stick model) through 60° 
rotation about the C-C bond. As a consequence, the 
side chain of residue I91 undergoes rotation from an 
eclipsed to a trans conformation. Residues P201, L203 
and V134 are involved in hydrophobic interactions with 
the cofactor’s Cppropyl group. Loops 4,5 and 7,8 interact 
via an H-bond between C205S-O and V134-Ocarbonyl. 
 
Full atomic occupancy was found for the anchoring ben-
zene sulfonamide moiety.   
However, limited density for the methylpyridine, Cp*, Cl 
and the terminal phenylsulfonamide suggests partial 
dissociation of the metal moiety and increased flexibility 
of the methylpyridine and the terminal phenylsulfona-
mide. The latter group was modeled in an Ir-binding 
eclipsed (30% occupancy) and non-binding anticlinal 
conformation (70% occupancy). In this structure, the 
cofactor causes the L140M side chain to adopt one con-
formation only, whereas L197M, which is closer to the 
flexible methylpyridine, adopts two conformations as in 
the apo-a2 structure. C205S, which adopts the same con-
formation in the cofactor-bound and apo forms, forms an 
H-bond with the carbonyl oxygen of V134. For [(5-
Cppropyl)Ir(pico)Cl] 2  a2, all atoms of the cofactor 
could be modeled with 100% occupancy (Figure 2, and 
Supporting Figure S3b). The metal complex adopts (R)-
configuration. Upon cofactor binding, an attractive CH/ 
interaction between I91-C and the F130-phenyl is dis-
rupted (Figure 2, magenta) but is compensated by a new-
ly formed CH/ bond between the methyl group of (pro-
pyl)C5Me4 and F130-phenyl (Figure 2, red dashed ar-
row). A similar interaction was also present in the crystal 
structure of a [(6-C6Me6)Ru(bispyridine)]  WT 
hCAII.53 Additionally, in this structure, both side chains 
L140M and L197M adopt a single conformation (Sup-
porting Figure S3b). The side chain of C205S adopts 
both conformations observed in the [(5-Cp*)Ir(pico)Cl] 
1  WT hCAII and in apo-a2 which forms an H-bond 
with the carbonyl oxygen of V134.  
   To gain insight into substrate recognition by the 
ATHase active site, derivatives of the salsolidine precur-
sor with a single methoxy group in position 6- (4) or 7- 
(5) and the desmethoxy substrate 6 were tested for trans-
fer hydrogenation with selected hybrid catalysts. The 
ATHase [(5-Cp*)Ir(pico)Cl] 1  a2 affords enantioen-
riched (S)-amines with 86, 85, 90 and 75 % ee for sub-
strates 3, 4, 5 and 6, respectively (Table 1, entries 7, 21, 
23 and 25). Similarly, screening [(5-Cp*)Ir(pico)Cl] 1  
d1 with substrates 3, 4, 5 affords the corresponding (S)-
amines in 87, 60 and 64 % ee respectively (Table 1, en-
tries 11, 22 and 24). Strikingly, the desmethoxy substrate 
6 affords the opposite (R)-enantiomer in 74 % ee with 
this mutant (Table 1, entry 26). This highlights the criti-
cal importance of the methoxy substituents on enantiose-
lectivity. The influence  of methoxy substituents on the 
substrate (irrespective of their substitution pattern) sug-
gest that the electron density on the arene may play a 
critical role in positioning one prochiral face of the sub-
strate to the Ir–H moiety.  
Outlook 
The results presented herein demonstrate that structure-
based computational amino acid sequence optimization 
with Rosetta Design allows to identify hCAII mutants 
with significantly increased affinity for an Ir-catalyst 
bearing a arylsulfonamide moiety. Improved protein-
cofactor stability correlates with both increased activity 
and enantioselectivity. Higher TON may relate to a re-
duced weight of non-productive conformations of the 
cofactor-protein assembly. Combining designed hCAII 
mutations with more hydrophobic Ir-catalyst 2 yields the 
most (S)-selective ATHase reported to date. The presence 
of methoxy substituents on the prochiral imine was 
shown to determine which enantiomer of the amine is 
produced preferentially. Structural characterization of 
catalyst 2 binding to hCAII a2 illustrates how embedding 
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 6 
the catalyst within the protein in a fixed orientation con-
tributes to increased selectivity. Future experiments will 
aim at applying Rosetta Design for the optimization of 
other artificial metalloenzymes including in silico scan-
ning of metal cofactor diversity. In addition, to further 
increase the stereoselectivity it can be envisaged to uti-
lize computational models of the (R)- and (S)-reaction 
transition states in the Rosetta protein sequence optimi-
zation procedure.40,54  
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